Logo image of 2HQ.DE

TILRAY BRANDS INC (2HQ.DE) Stock Fundamental Analysis

FRA:2HQ - Deutsche Boerse Ag - US88688T1007 - Common Stock - Currency: EUR

0.6168  -0.02 (-2.65%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 2HQ. 2HQ was compared to 52 industry peers in the Pharmaceuticals industry. The financial health of 2HQ is average, but there are quite some concerns on its profitability. While showing a medium growth rate, 2HQ is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year 2HQ has reported negative net income.
2HQ had a negative operating cash flow in the past year.
2HQ had negative earnings in each of the past 5 years.
In the past 5 years 2HQ reported 4 times negative operating cash flow.
2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCF2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

1.2 Ratios

2HQ has a worse Return On Assets (-5.94%) than 63.46% of its industry peers.
2HQ's Return On Equity of -7.17% is on the low side compared to the rest of the industry. 2HQ is outperformed by 63.46% of its industry peers.
Industry RankSector Rank
ROA -5.94%
ROE -7.17%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
2HQ.DE Yearly ROA, ROE, ROIC2HQ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 30.47%, 2HQ is doing worse than 78.85% of the companies in the same industry.
In the last couple of years the Gross Margin of 2HQ has declined.
The Profit Margin and Operating Margin are not available for 2HQ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
2HQ.DE Yearly Profit, Operating, Gross Margins2HQ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

2HQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 2HQ has more shares outstanding
The number of shares outstanding for 2HQ has been increased compared to 5 years ago.
The debt/assets ratio for 2HQ has been reduced compared to a year ago.
2HQ.DE Yearly Shares Outstanding2HQ.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
2HQ.DE Yearly Total Debt VS Total Assets2HQ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -0.17, we must say that 2HQ is in the distress zone and has some risk of bankruptcy.
2HQ's Altman-Z score of -0.17 is on the low side compared to the rest of the industry. 2HQ is outperformed by 63.46% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that 2HQ is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.10, 2HQ is doing good in the industry, outperforming 76.92% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.17
ROIC/WACCN/A
WACC8.66%
2HQ.DE Yearly LT Debt VS Equity VS FCF2HQ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

2HQ has a Current Ratio of 2.54. This indicates that 2HQ is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of 2HQ (2.54) is better than 84.62% of its industry peers.
2HQ has a Quick Ratio of 1.58. This is a normal value and indicates that 2HQ is financially healthy and should not expect problems in meeting its short term obligations.
2HQ's Quick ratio of 1.58 is amongst the best of the industry. 2HQ outperforms 80.77% of its industry peers.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.58
2HQ.DE Yearly Current Assets VS Current Liabilites2HQ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.05% over the past year.
The Revenue has grown by 18.38% in the past year. This is quite good.
2HQ shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.86% yearly.
EPS 1Y (TTM)86.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.09%
Revenue 1Y (TTM)18.38%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%8.87%

3.2 Future

2HQ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.07% yearly.
2HQ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.58% yearly.
EPS Next Y40.17%
EPS Next 2Y31.17%
EPS Next 3Y24.74%
EPS Next 5Y18.07%
Revenue Next Year14.2%
Revenue Next 2Y9.83%
Revenue Next 3Y8.35%
Revenue Next 5Y7.58%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
2HQ.DE Yearly Revenue VS Estimates2HQ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
2HQ.DE Yearly EPS VS Estimates2HQ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 2HQ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 2HQ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2HQ.DE Price Earnings VS Forward Price Earnings2HQ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

2HQ's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.43
2HQ.DE Per share data2HQ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

2HQ's earnings are expected to grow with 24.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.17%
EPS Next 3Y24.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 2HQ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

FRA:2HQ (3/7/2025, 7:00:00 PM)

0.6168

-0.02 (-2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-10 2025-01-10/bmo
Earnings (Next)04-07 2025-04-07/bmo
Inst Owners11.8%
Inst Owner ChangeN/A
Ins Owners0.29%
Ins Owner ChangeN/A
Market Cap578.35M
Analysts71.58
Price Target1.89 (206.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-77.02%
Min EPS beat(2)-145.1%
Max EPS beat(2)-8.93%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-435.3%
EPS beat(12)2
Avg EPS beat(12)-369.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.61%
Min Revenue beat(2)-10.57%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-5.74%
Min Revenue beat(4)-10.57%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-1.66%
Revenue beat(12)1
Avg Revenue beat(12)-2.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.64%
PT rev (3m)-14.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.32%
EPS NY rev (1m)0%
EPS NY rev (3m)-75.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.76
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 1.04
EV/EBITDA 23.43
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.81
BVpS3.41
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.94%
ROE -7.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.47%
FCFM N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score6
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA 12.11
Cap/Depr 24.08%
Cap/Sales 3.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.58
Altman-Z -0.17
F-Score6
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.09%
EPS Next Y40.17%
EPS Next 2Y31.17%
EPS Next 3Y24.74%
EPS Next 5Y18.07%
Revenue 1Y (TTM)18.38%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%8.87%
Revenue Next Year14.2%
Revenue Next 2Y9.83%
Revenue Next 3Y8.35%
Revenue Next 5Y7.58%
EBIT growth 1Y38.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.21%
EBIT Next 3Y37.41%
EBIT Next 5Y24.25%
FCF growth 1Y9.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.73%
OCF growth 3YN/A
OCF growth 5YN/A